isoxazoles has been researched along with Atrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atkins, CM; Chapalamadugu, M; Gee, KW; Hogenkamp, D; Johnson, NH; Johnstone, T; London, SH; Titus, DJ | 1 |
| Bellamy, CO; Dhaun, N; Kluth, DC; MacIntyre, IM | 1 |
2 other study(ies) available for isoxazoles and Atrophy
| Article | Year |
|---|---|
Positive allosteric modulation of the α7 nicotinic acetylcholine receptor as a treatment for cognitive deficits after traumatic brain injury.
Topics: Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Anilides; Animals; Atrophy; Brain; Brain Injuries, Traumatic; Chronic Disease; Cognition Disorders; Conditioning, Classical; Fear; Isoxazoles; Long-Term Potentiation; Male; Maze Learning; Memory, Short-Term; Rats, Sprague-Dawley; Synaptic Transmission | 2019 |
Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney.
Topics: Amides; Antihypertensive Agents; Atrophy; Biomarkers; Biopsy; Endothelin Receptor Antagonists; Female; Fibrosis; Fumarates; Humans; Hypertension, Renal; Isoxazoles; Kidney; Middle Aged; Proteinuria; Pulmonary Fibrosis; Renal Insufficiency, Chronic; Renin; Scleroderma, Systemic; Thiophenes; Treatment Outcome | 2009 |